Pfizer Clostridioides Difficile Research Collaboration

Funding available in specified countries for co-developed research studies focused on understanding the burden of Clostridioides difficile infections in humans.

Pfizer Inc. is an American multinational pharmaceutical corporation founded in 1849 and headquartered in New York City. It is one of the world’s largest pharmaceutical companies.

Pfizer offers funding to support the global healthcare community’s independent initiatives (research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

The Clostridioides difficile (C. difficile) Research Collaboration competitive grant programme seeks to identify investigators with innovative research proposals who are interested in partnering with Pfizer and other like-minded investigators on co-developed research studies focused on understanding the burden of Clostridioides difficile (C. difficile) infections in humans.

Projects should focus on assessing the burden of Clostridioides difficile infections in adults aged 18 years and older, especially but not limited to healthy adults over 50 years old and high-risk adults aged 18 to 49 years old. Studies may be designed as population-based, hospital-based or outpatient setting-based studies. Applicants are encouraged to propose multi-centre studies or select a single hospital that serves a large and diverse area, whether in urban or rural settings.